Vaxchora

Phase 2

Allergy Therapeutics plc (AGY.L)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Cholera

View Full Landscape

Drug Information

Target Indication

Cholera

Clinical Trial

NCT03251495

Last updated: 8/29/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA4/1/2020

Vaxchora

Vaxchora is indicated for active immunisation against disease caused by Vibrio cholerae serogroup O1 in adults and children aged 2 years and older. This vaccine should be used in accordance with official recommendations.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

AGY.L

Allergy Therapeutics plc

Pharmaceutical Preparations•Europe•AIM

Related Pipeline

SUBLIVAC FIX BirchPhase 3

Allergic Rhinitis

SUBLIVAC® Grasses treatmentPhase 3

Rhinitis, Allergic, Seasonal

Anti-HIV Immune Serum Globulin (Human)Phase 3

HIV Infections

Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)Phase 3

Eosinophilic Gastrointestinal Disorders (EGIDs)

PURETHAL Mites 50,000 AUeq/mlPhase 3

House Dust Mite Allergy

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts